Injectables and Implantables Are Next Generation of HIV Prevention

On behalf of IFARA, Fred Schaich spoke with Carl Dieffenbach, Ph.D., about the HIV prevention research presented at this year's International AIDS Conference. Results from the HVTN 100 trial in South Africa, which tested a preventive vaccine modified specifically for that country, exceeded expectations, paving the way for a large-scale efficacy trial of the compound that will start this November. The AMP study in Germany, the Americas and Sub-Saharan Africa is testing an infusion of one broadly neutralizing antibody, VRC01, every eight weeks to learn whether this will prevent the acquisition of HIV. If it proves to be 50% effective, the vaccine might be licensed in South Africa, paving the way for more extensive clinical trials. A phase IIa safety study is looking at cabotegravir as an injectable pre-exposure prophylaxis agent. If it proves to be safe, licensing trials for that form of prevention might start within the next year. The next revolution in HIV prevention will be injectable and implantable forms of prophylaxis, Dieffenbach predicted.

Watch the video to learn more:

About the panelist:

  • Carl Dieffenbach, Ph.D., Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.